The BDN Opinion section operates independently and does not set news policies or contribute to reporting or editing articles elsewhere in the newspaper or on bangordailynews.com
Anne Graham of North Yarmouth is a Maine state representative, serving on the Health and Human Services Committee. She is a retired pediatric nurse practitioner.
I’m a retired pediatric nurse practitioner who spent over 40 years working in health care, and I know how much decisions made in Washington can affect patients back home. The Food and Drug Administration has enormous influence over the medicines people take, the vaccines they receive and the care they can access.
That’s why Heidi Overton’s nomination to lead the agency deserves a hard look.
The FDA commissioner should make decisions based on the evidence, especially when those decisions affect medicines millions of Americans rely on.
That responsibility carries particular weight in Maine. More than 690,000 Mainers live in rural communities, where provider shortages, long distances and transportation barriers can already make care harder to reach. Telehealth has helped bridge some of those gaps.
That makes Overton’s record on medication abortion especially concerning to me. She has questioned the safety of medication abortion and criticized the FDA’s decision to allow abortion pills through telehealth, even though telehealth access to mifepristone is especially important for rural patients in Maine. Sen. Susan Collins has defended mifepristone as an FDA-approved drug that has been extensively studied and has championed telehealth partnerships to improve healthcare access in rural Maine.
Overton, by contrast, called the Supreme Court’s decision overturning Roe v. Wade a “ huge victory for life” and argued for tighter restrictions on what she has called “ teleabortion.”
The question is how Collins will vote on Overton’s nomination.
If confirmed, Overton would lead the agency responsible for regulating mifepristone. That creates a fair question: Can Mainers have confidence that future decisions about the medication will follow the scientific evidence rather than positions she reached before taking the job?
Overton’s record on vaccines raises another concern.
Overton praised President Donald Trump’s August changes to federal childhood vaccine policy as “ a historic action” and supported giving parents the option of separating the combined measles, mumps and rubella vaccine into three shots. Republican Sen. Bill Cassidy, the physician who chairs the Senate committee responsible for considering her nomination, subsequently called her role in the vaccine changes “ almost disqualifying.”
Then there is the question of basic rigor.
Overton is the sole individual identified as an author in the metadata of the White House’s 2025 Make America Healthy Again report. The administration later corrected the report after journalists found nonexistent studies, incorrect links and other citation errors.
That is not a minor concern for someone seeking to run the FDA. This is an agency where accuracy, careful review and sound judgment can have real consequences for patients. The commissioner sets the tone for thousands of scientists, doctors and public-health professionals whose work depends on getting the facts right. When a major federal health report contains nonexistent studies and basic citation failures, the public deserves to know how those mistakes happened and what responsibility its authors take for them.
In my work on healthcare programs, I’ve learned that details matter. Facts matter. Accountability matters. They matter even more at an agency responsible for determining whether medicines and medical products are safe and effective.
The criticism of Overton also does not fall neatly along party lines. Kelly Ryerson, an ally of Robert F. Kennedy, has warned that “ corporate capture will thrive at the FDA.” under Overton and accused her of echoing industry talking points.
Taken together with Chairman Cassidy’s concerns, that criticism shows the questions about Overton are coming from different directions.
The FDA touches nearly every family in Maine. Whoever leads it will make decisions involving prescription drugs, vaccines, medical devices and treatments that people depend on every day. Mainers deserve an FDA commissioner who follows the evidence, exercises sound judgment and puts patients ahead of politics.
Heidi Overton’s record does not meet that standard.